Leaders in Pharmaceutical Business Intelligence (LPBI) Group

Roles at http://pharmaceuticalintelligence.com

Effective August 2, 2019 – nominated as Member of the Board

Effective June 23, 2020 – Appointed Chief Scientific Officer

• Senior Editor, Cancer – Volume One e-Book, Cancer Volume Two
• Senior Editor, Genomics – Volume One e-Book,
• Senior Editor, Genomics – Volume Two e-Book,
• Content Consultant, Series A: Cardiovascular, Volume One – Nitric Oxide
• EAW for the following Research Categories:
• • Cell Biology and Cell Circuits
  • Chemical Biology and its relations to Metabolic Disease
  • Disease biology, using small molecules toward the development of therapeutic drugs.
  • Cancer Biology and Innovations in Cancer Therapy

 

STEPHEN J. WILLIAMS, Ph.D.

Tel: 215 487 0259 (h)  610 331 1016 (c) Email: sjwilliamspa@comcast.net

Personal Bio

Personal Statement: My scientific career has centered on understanding the mechanisms underlying initiation of cancer, as well as the pharmacologic and toxicologic basis of chemotherapy. My research has focused on modeling the etiology and metabolic alterations of human ovarian cancer and malignant mesothelioma, using cellular, molecular and in-vivo strategies.  Current research focuses on growth factor cell signaling in mesothelioma. Altogether, my research goals have concentrated on the cellular stresses, and the resultant genetic and metabolic alterations which provide not only a fertile micro-environment for oncogenesis, tumor progression and disease etiology but also an opportunity for therapeutic development

 

Biography: For the onset of my scientific career I entered one of the first undergraduate toxicology programs in the country, at the Philadelphia College of Pharmacy & Science, and trained in various methodologies in toxicology and pharmacology, including research into effects of leukotrienes and leukotriene antagonists on  gastrointestinal motility. I continued with my research training at the University of Pennsylvania Institute for Environmental Medicine, studying the effects of hyperbaric oxygen, and free radicals on lung function and the pathology of Sudden Infant Death Syndrome.  I subsequently received my PhD in Pharmacology from Temple University, with my thesis, under Dr. Michael Sirover, involving the biochemical and pharmacologic effects on noncanonical protein functions in metabolism and DNA repair. Afterward, I continued with postdoctoral training in the Department of Pharmacology under an NCI-PRAT fellowship and in the Ovarian Cancer Program in the laboratory of Dr. Thomas Hamilton.  My research involved determination of mechanisms of cisplatin resistance in ovarian cancer, discovering genes causal in early ovarian oncogenesis, and development of animal ovarian tumor models useful for determining ovarian cancer driver genes, determining chemotherapeutic efficacy, and development of imaging and surrogate tumor biomarker methods for detection of ovarian tumor burden in in-vivo ovarian cancer models.  To this end, I developed one of the first, and patented, porcine ovarian tumor models, and with colleagues, additional models to measure intraperitoneal ovarian cancer using both surrogate tumor markers and MRI imaging methodology useful for chemotherapeutic evaluation.

As scientific research and information was entering a new explosive age of massive data, I decided to assist Dr. Aviva Lev Ari in her venture Leaders in Pharmaceutical Business Intelligence, in developing a methodology of scientific curation, in collaboration with Dr. Larry Bernstein and a worldwide network of expert scientists and clinicians.   This effort culminated in the development of an influential web 2.0 platform for the curation, organization, and dissemination of scientific and biomedical findings in addition of the creation of 16 medical e-books on multiple topics.  As such I became senior editor on two volumes, an e-book series on Cancer and a series on Genomics.

Concurrently I was designated an adjunct professor in Temple University College of Science & Technology, teaching a course on Cell Signaling and Cancer Biology, as well as an associate professor in the Sbarro Health Research Organization where I head the grants department including grants management and administration.  Currently I also decided to continue my research efforts into understanding events causal in early oncogenesis and joined the research organization ISOPROG, where we have been researching autocrine growth factor loops involved in the malignant phenotype in mesothelioma and other cancer types.

As a result of the aforementioned endeavors, I have multiple peer-reviewed publications and book chapters as well as whole books in the fields of cancer, genomics, and personalized oncology.  In addition, I am a frequent reviewer for such journals such as Cancer Research, Cancers, the Journal of Cellular Physiology, and others.  I am a member of the AAAS, AACR, Mid Atlantic Pharmacology and Mid Atlantic Toxicology Society.

AREAS OF EXPERTISE     

• Molecular Biology and Biochemistry: Transitional research, recombinant DNA technologies; RNA/DNA purification and analysis; real-time PCR and primer design; DNA methylation; Western analysis (quantative); ELISA; DNA repair assays; enzyme kinetics; analysis of cellular redox status; protein modification; enzyme and protein purification; column chromatography; HPLC; immunohistochemistry; reporter gene assays.
• Cellular: Primary cell culture and isolation; development and establishment of cell lines (primary and tumorigenic, stable lines generation); flow cytometry; Guava single cell analysis; soft agar colony assay; cell proliferation/toxicity assays; in-vitro transformation.
• In-Vivo: Small animal handling and colony maintenance; development of animal models of ovarian cancer; in-vivo preclinical drug evaluation; necropsy and gross pathology; small animal imaging.

 

PUBLICATIONS with Leaders in Pharmaceutical Business Intelligence

 

Series A: e-Books on Cardiovascular Diseases

Volume One: Perspectives on Nitric Oxide

Sr. Editor: Larry Bernstein, MD, FCAP, Editor: Aviral Vatsa, PhD and Content Consultant: Stephen J Williams, PhD

http://www.amazon.com/dp/B00DINFFYC

 

Series B: e-Books on Genomics & Medicine

 

Genomics Orientations for Personalized Medicine, on Amazon since 11/23/2015

Sr. Editor: Larry Bernstein, MD, FCAP, Editor: Stephen J Williams, PhD

http://www.amazon.com/dp/B018DHBUO6

 

Volume Two: Latest in Genomics Methodologies for Therapeutics: Gene Editing, NGS & BioInformatics, Simulations and the Genome Ontology

Senior Editor, Stephen J. Williams, PhD, and Editor: Aviva Lev-Ari, PhD, RN

Work-in-Progress

Series C: e-Books on Cancer and Genomics

Volume One: Cancer Biology and Genomics for Disease Diagnosis

Editors: Stephen J Williams, PhD, Dror Nir, PhD and Tilda Barliya, PhD, Ritu Saxena, PhD

Volume Two: Cancer Therapies: Metabolic, Genomics, Interventional, Immunotherapy and Nanotechnology in Therapy Delivery

 

PUBLICATIONS in Open Access Online Scientific Journal

http://pharmaceuticalintelligence.com/

Cancer

 

Williams, S.J. July 1, 2014. Good and Bad News Reported for Ovarian Cancer Therapy

http://pharmaceuticalintelligence.com/2014/07/01/good-and-bad-news-reported-for-ovarian-cancer-therapy-2/

Williams, S.J. June 17, 2014. Can Mobile Health Apps Improve Oral-Chemotherapy Adherence? The Benefit of Gamification.

http://pharmaceuticalintelligence.com/2014/06/17/can-mobile-health-apps-improve-oral-chemotherapy-adherence-the-benefit-of-gamification/

Williams, S.J. June 11, 2014. The SCID Pig II: Researchers Develop Another SCID Pig, And Another Great Model For Cancer Research

http://pharmaceuticalintelligence.com/2014/06/11/the-scid-pig-ii-researchers-develop-another-scid-pig-and-another-great-model-for-cancer-research/

Williams, S.J. May 6, 2014. The Cancer Research Concentration @ Leaders in Pharmaceutical Business Intelligence

http://pharmaceuticalintelligence.com/2014/05/06/the-cancer-concentration-leaders-in-pharmaceutical-business-intelligence/

Williams, S.J. April 4, 2014. Heroes in Medical Research: Developing Models for Cancer Research

http://pharmaceuticalintelligence.com/2014/04/04/heroes-in-medical-research-developing-models-for-cancer-research/

Williams, S.J. January 3, 2014. Loss of Gene Islands May Promote a Cancer Genome’s Evolution: A new Hypothesis on Oncogenesis

http://pharmaceuticalintelligence.com/2014/01/23/loss-of-gene-islands-may-promote-a-cancer-cells-survival-proliferation-and-evolution-a-new-hypothesis-and-second-paper-validating-model-on-oncogenesis-from-the-elledge-laboratory/

Williams, S.J. November 23, 2013. Liver Toxicity halts Clinical Trial of IAP Antagonist for Advanced Solid Tumors

http://pharmaceuticalintelligence.com/2013/11/25/liver-toxicity-halts-clinical-trial-of-iap-antagonist-for-advanced-solid-tumors/

Williams, S.J. October 11, 2014. The SCID Pig: How Pigs are becoming a Great Alternate Model for Cancer Research

http://pharmaceuticalintelligence.com/2013/10/10/the-scid-pig-how-pigs-are-becoming-a-great-alternate-model-for-cancer-research/

Williams, S.J. September 4, 2013. Issues in Personalized Medicine: Discussions of Intratumor Heterogeneity from the Oncology Pharma forum on LinkedIn

http://pharmaceuticalintelligence.com/2013/09/04/issues-in-personalized-medicine-discussions-of-intratumor-heterogeneity-from-the-oncology-pharma-forum-on-linkedin/

Williams, S.J. August 7, 2013. Nitric Oxide Mitigates Sensitivity of Melanoma Cells to Cisplatin  

http://pharmaceuticalintelligence.com/2013/08/07/nitric-oxide-increases-sensitivity-of-melanoma-cells-to-cisplatin/

Williams, S.J. June 13, 2013. Combining Nanotube Technology and Genetically Engineered Antibodies to Detect Prostate Cancer Biomarkers

http://pharmaceuticalintelligence.com/2013/06/13/combining-nanotube-technology-and-genetically-engineered-antibodies-to-detect-prostate-cancer-biomarkers/

Williams, S.J. May 30, 2013. New scheme to routinely test patients for inherited cancer genes

http://pharmaceuticalintelligence.com/2013/05/30/new-scheme-to-routinely-test-patients-for-inherited-cancer-genes/

Williams, S.J. April 17,2013. Heroes in Medical Research: Dr. Robert Ting, Ph.D. and Retrovirus in AIDS and Cancer

http://pharmaceuticalintelligence.com/2013/04/17/heroes-in-medical-research-dr-robert-ting-ph-d-and-retrovirus-in-aids-and-cancer/

Williams, S.J. April 10, 2013. Issues in Personalized Medicine in Cancer: Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing

http://pharmaceuticalintelligence.com/2013/04/10/issues-in-personalized-medicine-in-cancer-intratumor-heterogeneity-and-branched-evolution-revealed-by-multiregion-sequencing/

Williams, S.J. March 13, 2013. Personalized Medicine: Clinical Aspiration of Microarrays

http://pharmaceuticalintelligence.com/2013/03/13/personalized-medicine-clinical-aspiration-of-microarrays/

Williams, S.J. March 12, 2013. AMPK Is a Negative Regulator of the Warburg Effect and Suppresses Tumor Growth In Vivo

http://pharmaceuticalintelligence.com/2013/03/12/ampk-is-a-negative-regulator-of-the-warburg-effect-and-suppresses-tumor-growth-in-vivo/

Williams, S.J. February 10, 2014. Rewriting the Mathematics of Tumor Growth; Teams Use Math Models to Sort Drivers from Passengers

http://pharmaceuticalintelligence.com/2013/02/10/rewriting-the-mathematics-of-tumor-growth-teams-use-math-models-to-sort-drivers-from-passengers/

Williams, S.J. February 3, 2013. Genome-Wide Detection of Single-Nucleotide and Copy-Number Variation of a Single Human Cell

http://pharmaceuticalintelligence.com/2013/02/03/genome-wide-detection-of-single-nucleotide-and-copy-number-variation-of-a-single-human-cell/

Williams, S.J. January 12, 2013. Heroes in Medical Research: Barnett Rosenberg and the Discovery of Cisplatin

http://pharmaceuticalintelligence.com/2013/01/12/heroes-in-medical-research-barnett-rosenberg-and-the-discovery-of-cisplatin/

Williams, S.J. January 3, 2013. Differentiation Therapy – Epigenetics Tackles Solid Tumors

http://pharmaceuticalintelligence.com/2013/01/03/differentiation-therapy-epigenetics-tackles-solid-tumors/

Williams, S.J. November 30, 2012. Prostate Cancer Cells: Histone Deacetylase Inhibitors Induce Epithelial-to-Mesenchymal Transition

http://pharmaceuticalintelligence.com/2012/11/30/histone-deacetylase-inhibitors-induce-epithelial-to-mesenchymal-transition-in-prostate-cancer-cells/

Williams, S.J. October 31, 2012. How Mobile Elements in “Junk” DNA Promote Cancer – Part 1: Transposon-mediated Tumorigenesis

http://pharmaceuticalintelligence.com/2012/10/31/how-mobile-elements-in-junk-dna-prote-cacner-part1-transposon-mediated-tumorigenesis/

Williams, S.J., reporter, June 19, 2014. Second Annual Single-Cell Sequencing of Cancer Rountable August 20,21, 2014 Washington DC

http://pharmaceuticalintelligence.com/2014/06/19/second-annual-single-cell-sequencing-of-cancer-rountable-august-2021-2014-washington-dc/

Williams, S.J. March 27, 2013. Ethical Concerns in Personalized Medicine: BRCA1/2 Testing in Minors and Communication of Breast Cancer Risk

http://pharmaceuticalintelligence.com/2013/03/27/ethical-concerns-in-personalized-medicine-brca12-testing-in-minors-and-communication-of-breast-cancer-risk/

 

 

Toxicology

 

Williams, S.J. November 20, 2012. FDA Guidelines For Developmental and Reproductive Toxicology (DART) Studies for Small Molecules

http://pharmaceuticalintelligence.com/2012/11/20/fda-guidelines-for-developmental-and-reproductive-toxicology-dart-studies-for-small-molecules/

Williams, S.J. November 7, 2012. Report on the Fall Mid-Atlantic Society of Toxicology Meeting “Reproductive Toxicology of Biologics: Challenges and Considerations:

http://pharmaceuticalintelligence.com/2012/11/07/report-on-the-fall-mid-atlantic-society-of-toxicology-meeting-reproductive-toxicology-of-biologics-challenges-and-considerations/

Williams, S.J. October 29, 2013. Heroes in Medical Research: Dr. Carmine Paul Bianchi Pharmacologist, Leader, and Mentor

http://pharmaceuticalintelligence.com/2013/10/29/heroes-in-medical-research-dr-carmine-paul-bianchi-pharmacologist-leader-and-mentor/

Williams, S.J. February 24, 2013. Mobilizing Scientific Societies: Editorial by Science Editor-in-Chief Dr. Bruce Alberts

http://pharmaceuticalintelligence.com/2013/02/24/drl-invests-in-projects-to-improve-the-effectiveness-of-stem-learning-for-people-of-all-ages-its-mission-includes-promoting-innovative-research-development-and-evaluation-of-learning-and-teaching-a/

Williams, S.J. September 24, 2012. Nitric Oxide Covalent Modifications: A Putative Therapeutic Target?

http://pharmaceuticalintelligence.com/2012/09/24/nitric-oxide-covalent-modifications-a-putative-therapeutic-target/

 

Williams, S.J. May 14, 2014. The Bioscience Crowdfunding Environment: The Bigger Better VC?

http://pharmaceuticalintelligence.com/2014/05/14/the-bioscience-crowdfunding-environment-the-bigger-better-vc/

Williams, S.J. February 24, 2014. Tycho Brahe, where art thou? Today’s Renaissance of the Self-Funded Scientist!

http://pharmaceuticalintelligence.com/2014/02/24/tycho-brahe-where-art-thou-todays-renaissance-of-the-self-funded-scientist/

Williams, S.J. May 15, 2013. Finding the Genetic Links in Common Disease: Caveats of Whole Genome Sequencing Studies

http://pharmaceuticalintelligence.com/2013/05/15/finding-the-genetic-links-in-common-disease-caveats-of-whole-genome-sequencing-studies/

 

 

PROFESSIONAL EXPERIENCE

01/2015-present        Grants Manager &  Associate Professor, Sbarro Health Research Organization(SHRO, Philadelphia PA) and ISOPROG {Somatogene Institute for Personalised Oncology and Onco­Genomic Research}(Italy, www.isoprog.org/en/ )

Senior Scientist with ISOPROG researching mechanisms of malignant mesothelioma progression.  Environmental impacts of carcinogens in subpopulations of central Sicily. Responsible for co-writing NIH, NCI, and Foundation grants for SHRO.  Research Associate collaborating with  Pierluigi Scalia, M.D., Ph.D. Assistant Research Professor SHRO Research Professor and Director ISOPROG (Italy), including all animal protocols, budgetary information, and administrative support sections for all grant applications.

01/2018-present        Adjunct Professor, Temple University Biology Department College of Science & Technology, Philadelphia PA

Course Instructor for Biol 3373 Cell Signaling and Motility

08/2012-present        Senior Editor, Chief Scientific Officer, Pharmaceutical Business Intelligence, www.pharmaceuticalintelligence.com

Pharmaceutical Business Intelligence, www.pharmaceuticalintelligence.com

Chief Scientific Officer guiding the venture developing and structuring an online scientific/medical curative knowledge database for AI and offering expertise in cancer research and toxicology.  LPBI Group has developed a subscription base of over 2 million e-readers.

• Co-editor of cancer and genomics medical e-books and assisted on 14 other medical e-books by coordinating international effort and providing information technology & web development expertise.
• Coordinated deals with multiple biotech startups to expand funding options, and providing liaison with medical and academic centers
• Developing machine learning processes for analysis of curated biomedical informatic content
• Co-developed methodology for increasing and measuring Sachs Associates social-media conference coverage impact, and engagement through coordinated Twitter and blog environments

(2006-4/2012)RESEARCH ASSOCIATE – Dept of Medical Oncology Fox Chase Cancer Center, Philadelphia, PA

(laboratory PI Thomas C. Hamilton)

Developed innovative protocols in ovarian cancer research to determine mechanisms of altered vitamin A metabolism in ovarian cancer and resultant effects on tumorigenicity and ovarian cancer stem cell phenotype. Secured significant funding for multiple projects by identifying resources and submitting intelligent and accessible grant requests. Developed and patented a porcine model of ovarian cancer, useful for testing the safety and efficacy of adenoviral gene therapies. Developed human ovarian tumor surrogate marker for corporate preclinical drug study.  Wrote and awarded two internal grants as Co-Principal Investigator.

Discovered the molecular mechanisms by which alteration of vitamin A metabolism, CRBP1 expression and redox status alters the tumorigenic phenotype of ovarian cancer using novel cell culture, inducible mouse models and molecular analysis.  Work resulted in three peer-reviewed publications, one review and one international meeting abstract.

Determined the mechanism of complete loss of vitamin A metabolism in human ovarian cancer via complete loss of ALDH1A2 in human ovarian cancer specimens

Developed human ovarian tumor surrogate marker for preclinical drug study for Corporation (2 awarded funding agreements). Provided excellent liaison with multi-tier personnel in both industry, clinical and scientific community throughout project timeline.

Designed novel porcine ovarian cancer model for collaborative project with University of Alabama, Birmingham

Collaborated in studies showing utility of MRI in evaluating chemotherapy response in GEM ovarian tumor model

Fox Chase Cancer Center, Philadelphia, PA.

(1998-2006)

POSTDOCTORAL ASSOCIATE – Dept. of Medical Oncology

(laboratory PI Thomas C. Hamilton)

Discovered that decreased expression of retinol-binding proteins is associated with malignant transformation of the ovarian surface epithelium. Conducted research on a diversity of multiple funded projects in ovarian cancer research including mechanisms of cisplatin resistance, molecular and environmental changes involved in ovarian oncogenesis, and development of cell-based assays and animals models.

Translated findings of CRBP1 loss in rat ovarian cancer model to human ovarian cancer via by developing real-time PCR protocols.

Determined importance of AKT signaling toward p21 expression and DNA damage response after cisplatin/paclitaxel exposure in sensitive/resistant ovarian cancer cell lines

Discovered complete loss of CRBP1 expression in cohorts of micro-dissected human ovarian cancer tissues using real-time PCR.

Findings led to successfully funded RO1, three peer-reviewed publications, one book chapter and four meeting abstracts.

Keen leadership of laboratory team including handling of laboratory safety.

Assisted in grant, report and manuscript preparation.

­­­­­­

Institute for Environmental Medicine, University of Pennsylvania

(1990-1988)

RESEARCH SPECIALIST

Conducted thorough investigation on cell signaling mechanisms involved in surfactant secretion from pulmonary type II pneumocytes after environmental changes.

Cell isolation and culture of primary rat type II pneumocytes; isolated lung perfusion model.

Research resulted in three meeting abstracts.

Cytogen Corporation, Princeton, NJ.

(1987)

TOXICOLOGIST INTERN

Provided efficient performance following strict protocols in dosing of mice and laboratory duties for various research experiments including detailed observation reporting/monitoring and result translation. Performed offsite laboratory set up adhering to strict guidelines for safety and efficacy.

Philadelphia College of Pharmacy and Science

(1987-1988)

PHARMACOLOGY RESEARCH ASSISTANT INTERN

Created protocols, optimized experimental conditions and conducted experiments in the investigation of effects of leukotriene antagonist on gallbladder and atrial contraction in guinea pigs.

 EDUCATION

Doctor of  Philosophy (Ph.D) in Pharmacology

Temple University School of Medicine, Philadelphia, PA   September 1998

Bachelor of Science in Toxicology

Philadelphia School of Pharmacy and Science, Philadelphia, PA    May 1988

PATENTS HELD       

U.S. Provisional Patent # 0149-PO464US01: Patent application title: Cancer Compositions, Animal Models, and Methods of Use Thereof. Development of a porcine model of epithelial ovarian cancer.

AWARDS AND HONORS

NIH Pharmacology Research and Training Fellowship, Fox Chase Center, 1998

Doctoral Dissertation Research Award, Temple University, 1998

NCI Training Grant, Temple University, 1994-1996

University Fellowship, Temple University, 1990-1992

                                                        ACADEMIC SERVICE      

 

Adjunct Professor: Temple University, Biology CST; TUBiol3373 Cell Signaling & Motility; course instructor

Tutor in Pharmacology: Wyzant, Inc.

Graduate Student Teaching Assistant:   Medical Pharmacology (Temple University): Designed and taught reviews and quizzes for medical student for chemotherapeutic, cardiac and metal toxicology sections

Mentor:  Mentored High School teacher in laboratory techniques

Mentor:  Mentored High School teacher in MASOT sponsored program

Mentor:  Mentored student in design, conduct and presentation for school science fair – won first prize.

 

Ad hoc reviewer for:-

Journal Cellular Physiology

Cancers

Clinical Cancer Research

Cancer Research

Medicinal Chemistry

Gynecologic Oncology

International J. of Cancer

Biology

 

Professional Memberships

American Association for Cancer Research

Mid-Atlantic Society of Toxicology

Mid-Atlantic Society of Pharmacology

American Association for the Advancement of Science

International Society for Biocuration

 Certifications

AALAS       Animal Technician

EPA Region III Pennsylvania – Asbestos Abatement Supervisor

Pharmacovigilance ACPE Certification

Fox Online Teaching Program (Fox School of Business, Temple University)

 

              Publications        

Scalia, P.; Williams, S.; Luca’, R.; Giordano, A.; Bucci, E. Genetic and Cell biology Discriminants of Sars-CoV2 Infection and Susceptibility to Covid-19 pulmonary complication. European Journal of Molecular & Clinical Medicine 2020, 7, 05-09.

Scalia, P.; Williams, S.J. An Expert Patients-for-Patients integrated Biobanking-CRO Operational Model for Sustainable Personalized Oncology. Biomedical Journal of Scientific and Technical Research 2020, 26, 17, doi:10.26717/BJSTR.2020.25.004367.

Scalia, P.; Giordano, A.; Williams, S.J. The IGF-II-Insulin Receptor Isoform-A Autocrine Signal in Cancer: Actionable Perspectives. Cancers 2020, 12, doi:10.3390/cancers12020366

P. Scalia, S.J. Williams, A. Giordano, Core Element Cloning, Cis-Element Mapping and Serum Regulation of the Human EphB4 Promoter: A Novel TATA-Less Inr/MTE/DPE-Like Regulated Gene, Genes 10(12) (2019).

Scalia P, Pandini G, Carnevale V, Giordano A, Williams SJ. Identification of a novel EphB4 phosphodegron regulated by the autocrine IGFII/IRA axis in malignant mesothelioma. Oncogene 38: 5987-6001, 2019.

Scalia P., Williams S.J., Russo A., Giordano A. Actionable Molecular Targets in Cancer Liquid Biopsy. In: Russo A., Giordano A., Rolfo C. (eds) Liquid Biopsy in Cancer Patients. Current Clinical Pathology. Humana Press, Cham, 2017

Bernstein, L.H., Williams, S., Lev-Ari, A. Role of Calcium, the Actin Skeleton, and Lipid Structures in Signaling and Cell Motility. Archives of Medicine, 2015.

Williams, S.J. Nitric Oxide Covalent Modifications: A Putative Therapeutic Target? In: A. Lev-Ari, A. Vatsa, and L.H. Berstein (eds.), Perspectives on Nitric Oxide in Disease Mechanisms, Amazon Digital   Services, Inc., 2013.

Cvetkovic, D. and Williams, S.J. Ovarian preneoplasia. In: A. Nasir, S.C. Rubin, and G.P. Sutton (eds.), Preneoplastic Changes, Springer, Dordrecht, The Netherlands (in press).

Williams, S. J., Cvetkovic, D., Hamilton, T. C. Vitamin A Metabolism is Impaired in Human Ovarian Cancer. Gynecologic Oncology, 112: 637-645, 2009.

Cvetkovic, D. and Williams, S.J. Are there precursor lesions for ovarian cancer: a review. Serbian Archives of Medicine, 136(Suppl 1): 48-53, 2008.

Hensley, H., Quinn, B.A., Wolf, R.L., Litwin, S.L., Mabuchi, S., Williams, S.J., Williams, C., Hamilton, T.C., Connolly, D.C. Magnetic resonance imaging for detection and determination of tumor volume in a genetically engineered mouse model of ovarian cancer. Cancer Biology and Therapy, 6(11): 1717-1725, 2007.

Cvetkovic, D., Williams, S.J., and Hamilton, T.C.Loss of cellular retinol-binding protein 1 gene expression in microdissected human ovarian cancer. Clinical Cancer Research, 9: 1013-1020, 2003.

Roberts, D., Williams, S.J., Cvetkovic, D., Weinstein, J.K., Godwin, A.K., Johnson, S.W., and Hamilton, T. C. Decreased expression of retinol-binding proteins is associated with malignant transformation of the ovarian surface epithelium. DNA and Cell Biology, 21: 11-19, 2002.

Williams, S.J., and Hamilton, T.C.  Chemotherapeutic resistance in ovarian cancer. In: S.C. Rubin, and G.P. Sutton (eds.), Ovarian Cancer, pp.34-44.  Lippincott, Wilkins, and Williams, New York, 2000.

Mitsuuchi, Y., Johnson, S.W., Selvakumaran, M., Williams, S.J., Hamilton, T.C., and Testa, J.R.  The phosphatidylinositol 3-kinase/AKT signal transduction pathway plays a critical role in the expression of p21 ^{waf1/dip1/sdIl} induced by Cisplatin and Paclitaxel. Cancer Research 60: 5390-5394, 2000.

Williams, S.J., and Sirover, M.A. Mechanisms of Nitric Oxide-Protein Interactions: Species Specific NO-NAD+ Modification and Kinetic Alteration of the Glycolytic Protein Glyceraldehyde 3-Phosphate Dehydrogenase. Temple University Press, 1999.

ABSTRACTS

Cvetkovic, D., Williams, S. J., Hamilton, T. C. Loss of vitamin A metabolism in ovarian cancer. 19^th Meeting of the European Association for Cancer Research, Budapest, Hungary, 2006.

Williams, S.J., Cvetkovic, D., and Hamilton, T. C. Retinol conversion is impaired in human ovarian cancer cell lines relative to normal surface epithelial cells. 95^th Annual Meeting of the AACR, Orlando, FL, 2004.

Cvetkovic, D., Williams, S.J., and Hamilton, T.C. Loss of cellular retinol-binding protein 1 gene expression in microdissected human ovarian cancer. 10^th SPORE Investigators’ Workshop, Chantilly, VA, 2002.r

Cvetkovic, D., Williams, S.J., and Hamilton, T.C. Expression of cellular retinol-binding protein 1 is decreased in human ovarian cancer. 93^rd Annual Meeting of the AACR, San Francisco, CA, 2002.

Cvetkovic, D., Williams, S.J., and Hamilton, T.C. Validation of real-time RT-PCR detection of cellular retinol-binding protein 1 expression in human ovarian cancer. 9^th SPORE Investigators’ Workshop, Washington, DC, 2001.

Sen, N., Williams, S.J., and Chander, A. Secretion of phosphotidylcholine from lung epithelial type II cells in primary culture is inhibited by anion exchange inhibitors. FASEB, 1991.

Chander, A., and Williams, S.J. Alkalosis stimulates surfactant secretion and protein phosphorylation in lung epithelial type II cells. World Conference on Lung Health, 1990.

Chinoy, M.R., Williams, S.J., Dodia, C., and Fisher, A.B. Matrix influences lung surfactant uptake by primary cultures of adult rat granular pneumocytes. ASCB meeting, 1990

Completed Grants/Written and Co-written

Fox Chase Cancer Center Grant Supported Pilot Project: “Sleeping Beauty Based Ovarian Cancer Gene Discovery”;10/2010-09/2011; Co-Investigator

SPORE (Specialized Program in Ovarian Cancer Research Excellence) Pilot Project:     “Noncanonical Roles of CRBP1 in Ovarian Oncogenesis”; 08/2009-07/2010; Co-Investigator

Research Funding Agreements(2) for preclinical evaluation of antibody-based therapy in an in-vivo model of human ovarian cancer; 2009-2011 Co-P.I.

Assisted in writing of a successful NIH RO1 CA107195; Loss of Vitamin A Metabolism in Ovarian Oncogenesis; P.I. Thomas C. Hamilton; 06/2005 – 04/2010